Patrick Hoffmann

This inventor holds 39 USPTO granted patents and 36 published patent applications, plus 10 CIPO patents and 27 EPO patents, primarily in Bispecific Antibody Constructs. Top assignees: Amgen Research (Munich) Gmbh, Amgen Inc., Boehringer Ingelheim International Gmbh. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Hoffmann. Retrieved from https://idiyas.com/inventor/patrick-hoffmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39 (Patent Applications = 36)

% Patents Active = 100.0

CIPO Patents = 10 (Patent Applications = 4)

EPO Patents = 27 (Patent Applications = 44)

Average Co-Inventor Count = 8.8

ph-index = 10

Forward Citations = 318(Granted Patents)

Location History:

München, DE (2013)
Bad Heilbrunn, DE (2016 - 2022)
Munich, DE (2015 - 2024)

Company Filing History:

37 out of 77

Amgen Research (Munich) Gmbh

Boehringer Ingelheim International Gmbh

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Bispecific Antibody

CD3

BCMA

PSMA

CDH19

DLL3

Single Chain Antibody

T Cell Engaging

Nucleic Acids

Binding Molecules

Cross-Species

Anti-Leukocyte Adhesion

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441796 - Antibody constructs for CDH19 and CD3 (2025-10-14),

2. 12435139 - Antibody constructs for DLL3 and CD3 (2025-10-07),

3. 12428491 - PSMA and CD3 bispecific T cell engaging antibody constructs (2025-09-30),

4. 12304952 - Antibody constructs for DLL3 and CD3 (2025-05-20),

5. 12297292 - Antibody constructs for CDH19 and CD3 (2025-05-13),

6. 12281176 - Binding molecules for BCMA and CD3 (2025-04-21),

7. 12281175 - Binding molecules for BCMA and CD3 (2025-04-21),

8. 12281172 - Cross-species-specific PSMAxCD3 bispecific single chain antibody (2025-04-21),

9. 12152078 - Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3 (2024-11-26),

10. 11987633 - Cross-species-specific single domain bispecific single chain antibody (2024-05-21),

11. 11926666 - Bispecific antibody constructs for CDH3 and CD3 (2024-03-12),

12. 11884720 - Antibody constructs for MSLN and CD3 (2024-01-30),

13. 11661462 - Optimized cross-species specific bispecific single chain antibody contructs (2023-05-30),

14. 11591396 - Antibody constructs for DLL3 and CD3 (2023-02-28),

15. 11498964 - Antibody constructs for CDH19 and CD3 (2022-11-15),

Title: The Innovative Journey of Patrick Hoffmann

Introduction: Patrick Hoffmann, a visionary inventor hailing from Munich, DE, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Hoffmann's latest patents include cutting-edge advancements in artificial intelligence, renewable energy solutions, and sustainable transportation methods, showcasing his commitment to creating a more efficient and eco-friendly future.

Career Highlights: With a career spanning over two decades, Hoffmann has established himself as a leading figure in the tech industry, holding numerous patents and receiving accolades for his pioneering work in various fields.

Collaborations: Throughout his career, Hoffmann has collaborated with top research institutions, universities, and tech companies worldwide, fostering a culture of innovation and knowledge-sharing to drive progress in the industry.

Conclusion: Patrick Hoffmann's relentless pursuit of innovation and his passion for creating a positive impact on society continue to inspire the next generation of inventors and shape the technological landscape for years to come.

Profile summary based on public USPTO records.